Skip to content

Serotonin research published in 2021

Page 3 of 3: studies 41 to 59 of 59, newest first. Back to the serotonin overview

Studies

Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse

Journal of Neurochemistry March 12, 2021 Susan Schenk, Quenten Highgate 47 citations

Abstract Methylenedioxymethamphetamine (MDMA) is an amphetamine analogue that preferentially stimulates the release of serotonin (5HT) and results in relatively small increases in synaptic dopamine (DA). The ratio of drug‐stimulated increases in synaptic DA, relative to 5HT, predicts the abuse liability; drugs with higher DA:5HT ratios are more likely to be abused. Nonetheless, MDMA is a drug...

Eutylone and Its Structural Isomers Interact with Monoamine Transporters and Induce Locomotor Stimulation

ACS Chemical Neuroscience March 9, 2021 Grant C. Glatfelter, Donna Walther, Michael Evans‐brown et al. 29 citations

Synthetic cathinones are a class of new psychoactive substances that induce psychostimulant effects and pose risk for hospitalizations, overdose, and death. At the present time, derivatives of the synthetic cathinone, methylone, are being confiscated in nonmedical (i.e., recreational) drug markets worldwide. In particular, eutylone is a newly emerging methylone analog that possesses ethyl...

DOI: 10.1021/acschemneuro.0c00797 (opens in new tab) Full text (opens in new tab) Cathinone Pharmacology Dopamine transporter Monoamine neurotransmitter +9

Free energy calculations of the functional selectivity of 5-HT2B G protein-coupled receptor.

PLoS One March 4, 2021 Brandon L Peters, Jinxia Deng, Andrew L Ferguson 4 citations

G Protein-Coupled Receptors (GPCRs) mediate intracellular signaling in response to extracellular ligand binding and are the target of one-third of approved drugs. Ligand binding modulates the GPCR molecular free energy landscape by preferentially stabilizing active or inactive conformations that dictate intracellular protein recruitment and downstream signaling. We perform enhanced sampling...

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property

Frontiers in Pharmacology February 26, 2021 Guy A. Higgins, Nicole K. Carroll, Matthew A. Brown et al. 67 citations

Long term benefits following short-term administration of high psychedelic doses of serotonergic and dissociative hallucinogens, typified by psilocybin and ketamine respectively, support their potential as treatments for psychiatric conditions such as major depressive disorder. The high psychedelic doses induce perceptual experiences which are associated with therapeutic benefit. There have...

Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking.

ACS Pharmacology & Translational Science February 25, 2021 Eline Pottie, Olga V. Kupriyanova, Asher L. Brandt et al.

Serotonergic psychedelics are defined as compounds having serotonin 2A receptor (5-HT2AR) activation as an important pharmacological mechanism. These compounds include the phenylalkylamine class, containing substances with e.g. 2C-X structures (phenethylamines) or their N-methoxybenzyl analogues (NBOMes). Besides their abuse potential, psychedelics are increasingly recognized for having...

Increased kynurenine concentration attenuates serotonergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats through activation of aryl hydrocarbon receptor.

Neuropharmacology February 16, 2021 C. Abuin-Martínez, Rebeca Vidal, Maria D Gutierrez-Lopez et al.

3,4-Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has been shown to produce serotonergic damage in the brains of primates, including humans, and of rats. Tryptophan, the precursor of serotonin, is primarily degraded through the kynurenine (KYN) pathway, producing among others KYN, the main metabolite of this route. KYN has been reported as an endogenous agonist of the...

Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) on alcohol consumption in Long-Evans rats

Behavioural Pharmacology February 15, 2021 Michael D. Berquist, William E Fantegrossi

Supplemental Digital Content is available in the text. The objectives of this study were to determine alcohol consumption after administration of (R)(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) or naltrexone in Long–Evans rats, and to assess the effectiveness of these treatments based on individual differences in alcohol consumption. Adult male Long–Evans rats (N = 16) were given opportunities to...

Dual actions of 5‐MeO‐DIPT at the serotonin transporter and serotonin 5‐HT1A receptor in the mouse striatum and prefrontal cortex

Neuropsychopharmacology Reports February 6, 2021 Yoko Hagino, F. Scott Hall, George R. Uhl et al. 3 citations

Abstract Aims 5‐Methoxy‐ N , N ‐diisopropyltryptamine (5‐MeO‐DIPT) is a synthetic orally active hallucinogenic tryptamine analogue. The present study examined whether the effects of 5‐MeO‐DIPT involve the serotonin transporter (SERT) and serotonin 5‐hydroxytryptamine‐1A (5‐HT 1A ) receptor in the striatum and prefrontal cortex (PFC). Methods We investigated the effects of 5‐MeO‐DIPT on...

DOI: 10.1002/npr2.12161 (opens in new tab) Striatum 5-HT Receptor Serotonin transporter Dopamine +6

Psychedelic‐assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports

Pharmacology Research & Perspectives February 2, 2021 Benjamin J. Stewart, Jon G Dean, Adriana Koek et al. 15 citations

Abstract Functional neurological disorders (FNDs), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options. FNDs can present with sensory and/or motor symptoms, and, though they may mimic other neurological conditions, they are thought to occur via mechanisms other than...

DOI: 10.1002/prp2.688 (opens in new tab) Full text (opens in new tab) Serotonin Hallucinogens Psychosomatic medicine Receptor +9

Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT2A receptor activation

Scientific Reports January 21, 2021 April Contreras, Matthew Khumnark, Rochelle M. Hines et al.

Perception, emotion, and mood are powerfully modulated by serotonin receptor (5-HTR) agonists including hallucinogens. The 5-HT2AR subtype has been shown to be central to hallucinogen action, yet the precise mechanisms mediating the response to 5-HT2AR activation remain unclear. Hallucinogens induce the head twitch response (HTR) in rodents, which is the most commonly used behavioral readout of...

Cellular Uptake of Psychostimulants – Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers?

Frontiers in Pharmacology January 20, 2021 Ole Jensen, Muhammad Rafehi, Lukas Gebauer et al. 24 citations

Psychostimulants are used therapeutically and for illegal recreational purposes. Many of these are inhibitors of the presynaptic noradrenaline, dopamine, and serotonin transporters (NET, DAT, and SERT). According to their physicochemical properties, some might also be substrates of polyspecific organic cation transporters (OCTs) that mediate uptake in liver and kidneys for metabolism and...

Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice.

Neuroimage January 15, 2021 Joanes Grandjean, David Buehlmann, Michaela Buerge et al. 5 citations

Hallucinogenic agents have been proposed as potent antidepressants; this includes the serotonin (5-HT) receptor 2A agonist psilocybin. In human subjects, psilocybin alters functional connectivity (FC) within the default-mode network (DMN), a constellation of inter-connected regions that displays altered FC in depressive disorders. In this study, we investigated the effects of psilocybin on FC...

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

International Journal of Molecular Sciences January 15, 2021 Nakul Ravi Raval, Annette Johansen, Lene Lundgaard Donovan et al. 191 citations

A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and...

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

Psychopharmacology January 11, 2021 Nicole Leite Galvão‐coelho, Wolfgang Marx, Maria González et al. 143 citations

RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psychedelics have recently reemerged as a potential therapeutic treatment option. OBJECTIVE: We present the first meta-analytic review evaluating the clinical effects of classic serotonergic psychedelics vs placebo for mood state and symptoms of depression in both healthy...

Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials

Expert Opinion on Emerging Drugs January 2, 2021 Amna Majeed, Jiaqi Xiong, Kayla M Teopiz et al. 48 citations

INTRODUCTION: The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-based antidepressants invites the need for mechanistically novel treatments. Convergent evidence implicates glutamatergic signaling as a potential therapeutic target in MDD. AREAS COVERED: The synthesis herein of preclinical and clinical studies...

Drugs of Abuse Affecting 5-HT_2B Receptors

5-HT2B Receptors 2021 Dino Luethi, Matthias E. Liechti 3 citations

Stimulant and psychedelic drugs of abuse exert their effects through interactions with monoaminergic systems. Compared to other monoaminergic receptors and transporters, the 5-hydroxytryptamine 2B (5-HT_2B) receptor represents a relatively little studied target of serotonergic drugs of abuse. However, studies suggest the involvement of 5-HT_2B receptors in the mechanism of action of...

5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence.

Progress in Brain Research 2021 Guy A. Higgins, Edward M. Sellers 10 citations

Nicotine use and dependence, typically achieved through cigarette smoking, but increasingly through vape products, is the leading cause of preventable death today. Despite a recognition that many current smokers would like to quit, the success rate at doing so is low and indicative of the persistent nature of nicotine dependence and the high urge to relapse. There are currently three main forms...

Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder

Journal of Experimental Pharmacology 2021 Giacomo Grassi, Chiara Cecchelli, Luisa Vignozzi et al. 42 citations

Treatment-resistance is a frequent condition for obsessive-compulsive disorder (OCD). Over the past decades, a lot of effort has been made to address this issue, and several augmentation strategies of serotonergic drugs have been investigated. Antidopaminergic drugs are considered the first choice as augmentation strategy for treatment-resistant OCD patients, but they seem to work only for a...

DOI: 10.2147/jep.s255375 (opens in new tab) Serotonergic Riluzole Psychological intervention Obsessive compulsive +5

Safer Tripping: Serotonergic Psychedelics and Drug Checking. Submission and Detection Rates, Potential Harms, and Challenges for Drug Analysis

2021 Daan van der Gouwe, Tim Hirschfeld, Tomislav Majić et al.

Purpose of Review With the continuous emergence of new psychoactive substances, drug checking (DC) services are challenged by an increasingly complex drug market. Considering the resumed scientific and public interest in serotonergic psychedelics (SPs) like LSD, psilocybin, and 2C-B, we present the results of a literature search investigating the presence and proportion of SPs in DC samples....

DOI: 10.17169/refubium-40153 (opens in new tab) Full text (opens in new tab) Drug checking Drug testing Substance analysis Harm reduction services +16